**Spasticity in practice (SPACE), an international non-interventional study of botulinum neurotoxin type A in treatment-naïve subjects with spasticity**

**Supplemental data**

**Supplemental methods**

***HRQoL (SF-12)***

Health-related quality of life (HRQoL) was additionally assessed using the 12-item Short-form (SF-12) Health Survey [30]. Subjects completed the SF-12 questionnaires at their study centres during each injection visit and at home 4 weeks after the injection.

***HRQoL (EQ-5D dimensions)***

For each dimension of the EQ-5D descriptive system (Mobility, Self-care, Usual activities, Pain/discomfort and Anxiety/depression), subjects selected the statement that best described their health state on that day: no problems reported (normal condition, score 1), some problems reported (moderate impairment, score 2) and extreme problems reported (severe impairment, score 3).

**Supplemental Figure legends**

**Supplemental Figure 1.** Subject disposition at study baseline, and documented discontinuations

aAll subjects who received ≥1 injection of BoNT-A during the study; bincludes subjects in the safety population with no reported BoNT-A product administered at the first injection and documented reasons for discontinuation, n = 4; csubjects with available date of written consent and reported BoNT-A product administered at the first injection

**Supplemental Figure 2.** Most frequently treated muscles in the upper limb at A) Visit 1, B) Visit 8 and in the lower limb at C) Visit 1, D) Visit 8

Percentages are based on non-missing values

**Supplemental Figure 3.** Proportion of subjects with physicians’ assessment of tolerability rated as very good, good, moderate or poor at A) Visit 2 (evaluation of treatment cycle 1) and B) final visita (evaluation of treatment cycle 8)

aThe final visit occurred at the end of the study, subjects did not receive an injection at this point and only those who returned for assessment were included in the analysis

Percentages are based on non-missing values

N – total number of subjects assessed

**Supplemental Figure 4.** Proportion of subjects withEQ-5D ratings of no, some or extreme problems in all dimensions at Visit 2 (panels A–C) and the final visita (panels D–F) for all BoNT formulations

aThe final visit occurred at the end of the study, subjects did not receive an injection at this point and only those who returned for assessment were included in the analysis

Percentages are based on non-missing values

BoNT – botulinum neurotoxin; EQ-5D – EuroQoL 5-dimensions